Bioconjugate polysaccharide vaccines
Founded in 2016 by Mario Feldman and Christian Harding, Omniose develops bioconjugate polysaccharide vaccines targeting bacterial pathogens using a proprietary glycoconjugation platform.
कोई डेटा उपलब्ध नहीं
कोई FAQ उपलब्ध नहीं है।